Introduction: Trials of GLP-1 (glucagon-like peptide-1) medicines have changed the paradigm of obesity treatment. Diversity in trial participation is imperative considering that obesity disproportionately impacts marginalised populations worldwide. We performed a systematic review and meta-analyses to evaluate the representation of racialised and ethnically diverse populations in randomised controlled trials (RCTs) of GLP-1 medicines for obesity.
Methods: We searched PubMed/Embase/ClinicalTrials.gov. Prevalence of each racial/ethnic group was compared in relation to the USA, Canada, the UK, Brazil and South Africa. The geographical locations of the trial sites were extracted.
Results: 27 RCTs were identified (n=21 547 participants). Meta-analyses of prevalence demonstrated the vast predominance of white/Caucasians (79%) with smaller proportion of blacks (9%), Asians (13%), Indigenous (2%) and Hispanics (22%). The gaps in representation were evidenced by the significantly under-represented proportion of non-white individuals in these RCTs as compared with the prevalence of non-white individuals in the general population of the USA (-23%, p=0.002) and Canada (-34%, p<0.0001), reaching an alarming gap of -58% in relation to Brazil and striking under-representation of -68% as compared with South Africa. Similar discrepancies in proportions of blacks, Asians and Indigenous peoples as compared with reference nations were found. Moreover, the trial sites (n=1859) were predominately located in high-income countries (84.2%), in sharp contrast to the global prevalence of obesity that is predominantly in low-income and middle-income countries.
Conclusion: There are discrepancies in representation of racialised and ethnically diverse populations in obesity trials as compared with multiethnic populations worldwide. These data highlight the need for broader reform in the research process in order to ultimately address health inequities.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11603712 | PMC |
| http://dx.doi.org/10.1136/bmjgh-2024-017177 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Disruptive diversity: Exploring racial commodification in the Norwegian cultural field.
Br J Sociol
December 2024
Department of Sociology and Human Geography, University of Oslo, Oslo, Norway.
Scholars have suggested that the heightened focus on diversity in Western cultural fields may drive forms of racial commodification, impacting cultural representations of 'race'. However, few studies apply Bourdieu's theory of cultural production to understand how racial commodification may also disrupt field dynamics. This article aims to explore how racialised minority cultural producers in Norway experience the intensified focus on diversity within the cultural field.
View Article and Find Full Text PDFImpacts of the COVID-19 pandemic on access to sexual and reproductive health services for women and gender-diverse people with disabilities in Canada: a qualitative study.
Sex Reprod Health Matters
December 2024
Associate Professor, Department of Health and Society, University of Toronto Scarborough, Toronto, ON, Canada; Associate Professor, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Adjunct Scientist, Women's College Hospital Research Institute, Toronto, ON, Canada.
The COVID-19 pandemic has had a detrimental impact on sexual and reproductive health (SRH) and rights globally. However, little is known about the experiences of people with disabilities accessing SRH services during the COVID-19 pandemic. In this community-engaged qualitative study, we examined COVID-related impacts on access to SRH services for people with disabilities.
View Article and Find Full Text PDFRepresentation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps.
BMJ Glob Health
November 2024
Mount Sinai Hospital, Toronto, Ontario, Canada
Introduction: Trials of GLP-1 (glucagon-like peptide-1) medicines have changed the paradigm of obesity treatment. Diversity in trial participation is imperative considering that obesity disproportionately impacts marginalised populations worldwide. We performed a systematic review and meta-analyses to evaluate the representation of racialised and ethnically diverse populations in randomised controlled trials (RCTs) of GLP-1 medicines for obesity.
View Article and Find Full Text PDFHow do medical students deal with the topic of racism? A qualitative analysis of group discussions in Germany.
PLoS One
November 2024
Division for Ethics in Medicine, Department for Health Services Research, Carl von Ossietzky University of Oldenburg, Oldenburg, Germany.
Background: Anti-racism is part of the medical professional ethos. Nevertheless, racism pervades medicine on individual, institutional, and structural levels. The concept of habitus helps to understand deficiencies in enacting anti-racism in practice.
View Article and Find Full Text PDFWho counts in poverty research?
Sociol Rev
March 2024
Department of Political Science and Public Law, Institute of Government and Public Policy (IGOP), Autonomous University of Barcelona, Barcelona, Spain.
Mainstream poverty analysis currently renders certain people and degrees of privation more socially legible than others across high-income countries. This article examines how these hierarchies carry through to and corrupt wider social scientific analysis, inscribing differential value to actors and phenomena in ways that undermine social understanding and explanation. First, conventional approaches to poverty analysis and measurement obscure the prevalence of deep poverty, as well as those most subject to its violence.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!